Rhabdomyosarcoma

Could a Sequence-Specific Splice Switching Oligonucleotide and Antibody Therapy Combination Successfully Treat Rhabdomyosarcoma?
Could a Sequence-Specific Splice Switching Oligonucleotide and Antibody Therapy Combination Successfully Treat Rhabdomyosarcoma? 1024 683 Jessica Nye, PhD

Blocking alternative splicing may be a viable therapeutic intervention strategy for reducing tumor growth in rhabdomyosarcoma (RMS).   RMS is the most common pediatric soft tissue sarcoma and is associated with poor prognosis, a high rate of metastasis and recurrence. RMS tumors overexpress insulin growth factor (IGF)-2, making the IGF pathway a potential interventional target.…

read more
An Epigenetic Vulnerability for Rhabdomyosarcoma Among Children?
An Epigenetic Vulnerability for Rhabdomyosarcoma Among Children? 150 150 Jessica Nye, PhD

A deep classification of epigenetic machinery in rhabdomyosarcoma (RMS) tumors finds that the mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) complexes are essential for the stabilization of RMS.   A recent study, published in Nature Communications, by Ben Stanton, PhD, and colleagues focused on rhabdomyosarcoma (RMS), a lethal pediatric soft tissue malignancy. Fusion positive RMS (FP-RMS) has properties…

read more
Unraveling the Role of Pioneer Factors in Childhood Cancer
Unraveling the Role of Pioneer Factors in Childhood Cancer 150 150 Abbie Roth

New study implicates PAX3-FOXO1, an oncogenic driver of rhabdomyosarcoma, as a chimeric pioneer factor. Transcription factors are proteins that read the DNA sequences and can direct the transcription of that sequence into mRNA for translation into a protein. Transcription can become deregulated in cancer. Normally, transcription factors read sequences of DNA that are described as…

read more